Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Biopharmaceutical firm Altimmune has signed a teaming agreement with DynPort Vaccine to support US Government funding efforts for the development of its intranasal Covid-19 vaccine candidate, AdCOVID.
If successful, the partnership will be extended to programme management, drug development and regulatory support for the vaccine product.
DynPort has expertise in vaccine development and the preclinical, manufacturing, clinical and regulatory activities required for FDA licensure of new drug products.
Altimmune expects that the collaboration with DynPort will boost its capabilities to obtain and execute on US Government funding.